Actively Recruiting
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases - AiD GLIO Pilot Trial
Led by University Hospital, Basel, Switzerland · Updated on 2025-01-29
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating advanced diffusion-weighted MRI (ADW-MRI) to see if it can better distinguish true tumor progression from pseudoprogression in patients with glioblastoma or brain metastases. This pilot study aims to assess the feasibility of using ADW-MRI alongside standard follow-up MRI scans to improve detection accuracy. The study also examines how ADW-MRI results relate to tissue changes and damage in the central nervous system. Participants who have histopathologically confirmed glioblastoma or brain metastases with suspected tumor progression after first-line therapy and are candidates for elective surgical resection will undergo ADW-MRI before surgery. This advanced MRI technique adds about 30 minutes to the routine MRI exam and offers more sensitive detection of subtle tissue changes. If surgery occurs, the removed tissue will be analyzed and compared to the ADW-MRI findings. During the study, patients will receive the additional ADW-MRI scan preoperatively, and if surgery is performed, the tissue will be studied histopathologically. Researchers will correlate MRI results with tissue analysis to understand the technique's accuracy. The primary outcome is the correlation between ADW-MRI findings and histopathological results, assessed once at baseline. Participants will be monitored through their standard clinical care with no masking or placebo involved.
CONDITIONS
Brief Title
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progression on standard MRI after first line therapy who are candidates for elective surgical resection
- Able to give informed consent
- Age 18 years or older
You will not qualify if you...
- Contraindications to MRI such as claustrophobia, pacemaker or other implants without MRI approval, or pregnancy
- Patients in a life-threatening condition
- Patients needing emergent surgery
- Histopathological analyses of insufficient quality
- Unable to give informed consent
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants undergo advanced diffusion-weighted MRI (ADW-MRI) in addition to routine MRI to detect subtle tissue changes associated with tumor progression.
1 visit (in-person)
Duration - Varies depending on surgery scheduling
Participants who are candidates undergo surgical resection of suspicious tissue with histopathological analysis correlated to ADW-MRI findings.
1 surgical procedure visit
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
D
Dominik Cordier, PD Dr. med.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here